SYRS Insider Trading Activity and SEC Form 4 Filings
SYRS insider trading summary
No open-market insider purchases or sales of Syros Pharmaceuticals, Inc. (SYRS) have been reported on SEC Form 4 in the past 12 months.
Latest SYRS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 2, 2024 | Nancy A Simonian | Insider | Sell | $10K (37,070 @ $0.27) |
| Nov 25, 2024 | Nancy A Simonian | Insider | Sell | $36K (134,713 @ $0.27) |
| Nov 19, 2024 | Gerald E Quirk | Chief Legal & Compliance Offic | Sell | $10K (46,657 @ $0.22) |
| Nov 18, 2024 | Conley Chee | President & CEO | Sell | $27K (134,797 @ $0.20) |
| Nov 18, 2024 | Kristin Stephens | Chief Development Officer | Sell | $8K (36,133 @ $0.22) |
| Nov 18, 2024 | Jason Haas | Chief Financial Officer | Sell | $29K (137,803 @ $0.21) |
| Nov 18, 2024 | David Roth | Chief Medical Officer | Sell | $2K (12,099 @ $0.20) |
| Sep 12, 2024 | Jason Haas | Chief Financial Officer | Buy | $76K (45,344 @ $1.68) |
| Sep 11, 2024 | Conley Chee | President & CEO | Buy | $85K (50,000 @ $1.71) |
| Sep 11, 2024 | Jason Haas | Chief Financial Officer | Buy | $30K (19,293 @ $1.58) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.